INTRODUCTION
There is a growing movement in oncology to measure quality of cancer care with the ultimate goal of increasing accountability and improving outcomes. [1] [2] [3] [4] As outlined in a recent Institute of Medicine (IOM) report, fundamental to this movement is the need to elucidate the role that physicians play in promoting or impeding quality. 5 , 6 Yet even in breast cancer, one of the most commonly studied malignancies, the absence of national databases has been a key barrier preventing assessment of physician quality. 2, 7 Recent creation of nationally comprehensive cohorts of patients with cancer permits, for the first time, detailed assessment of the role that treating physicians play in promoting cancer care quality on a national basis. 7, 8 Use of needle biopsy to establish a diagnosis of breast cancer is an opportune quality measure in which to evaluate the role of the treating physician, because it was developed by the American College of Surgeons and endorsed by the National Quality Forum, 9 -15 yet prior studies suggest ongoing underuse. 15, 16 Accordingly, in a national cohort of Medicare beneficiaries age 66 years and older with incident breast cancer treated with breast-conserving surgery (BCS) and radiation, we sought to evaluate the influence of the patient's surgeon on use of needle biopsy. To validate the clinical benefit of needle biopsy, we also sought to determine whether receipt of needle biopsy was associated with a lower number of breast cancer surgeries before delivery of adjuvant radiation therapy.
METHODS

Cohort Creation
The study cohort was drawn from national Medicare data encompassing 100% of Medicare beneficiaries' final action institutional (inpatient and outpatient) and provider medical claims. A total of 89,712 incident breast cancers diagnosed from 2003 to 2007 in women age Ն 66 years with fee-for-service, Part A and B coverage and treated with BCS and radiation were identified using a validated algorithm with more than 90% positive predictive value (Appendix Tables A1 and A2 , online only). 16 Limiting the study cohort to patients who underwent BCS followed by radiation ensured a population for whom needle biopsy is the preferred diagnostic option.
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Outcomes
We evaluated three outcomes that follow the progression of most women through the continuum of breast cancer detection to treatment (Fig 1) . The first outcome is timing of surgeon consultation, with surgeon consultation before biopsy defined as an encounter with a surgeon within 60 days before biopsy and surgeon consultation after biopsy defined as the first encounter with a surgeon taking place after needle biopsy. The second outcome is use of needle biopsy (yes or no), with needle biopsy defined as either core biopsy or fine-needle aspiration within 60 days before initial BCS. The third outcome is the number of breast cancer surgeries, with single breast cancer surgery defined as all BCS and nodal surgery (if indicated) performed on a single date before radiation and multiple breast cancer surgeries defined as any BCS and/or nodal surgery occurring on more than one date before start of radiation (Appendix Table A2 ). For the purposes of these outcomes, BCS included claims for both segmental mastectomy and excisional biopsy, because both procedures can functionally serve as BCS (Appendix Table A2 ).
Covariates and Analyses
Patient and structural covariates are listed in Table 1 . Charlson comorbidity index was determined using claims generated from 12 months to 1 month preceding initial BCS. 17 Using ArcGIS v10.1 (ESRI, The Redlands, CA), distance from the centroid of the patient's zip code to the centroid of the zip code of the nearest radiologic facility performing a breast needle biopsy in the year of diagnosis was determined for each patient in the cohort (such radiologic facilities were located using nationally comprehensive Medicare claims of all patients with breast cancer).
Each patient was assigned a treating surgeon, defined as the surgeon who performed the initial BCS, in accordance with prior methods. 18 Each patient seen by any one of these surgeons before biopsy was also assigned a diagnosing surgeon, defined as the last surgeon to see the patient within 60 days before biopsy, which may or may not have been the same as the treating surgeon. Surgeon characteristics were determined via linkage to the American Medical Association Physician Master File.
Descriptive statistics characterized associations of patient-level covariates with needle biopsy receipt using Pearson's 2 , Wilcoxon, and CochranArmitage tests as appropriate. We also mapped the distribution of women in our cohort by hospital referral region (HRR) and overlaid the locations of all radiologic facilities performing needle biopsy (zip code centroids) to examine whether facilities were generally available in areas with large numbers of patients. To evaluate regional variation in receipt of needle biopsy, the proportion of patients receiving needle biopsy at the HRR level was calculated and The first outcome is timing of surgeon consultation ("Prebiopsy surgeon consultation?") and corresponds to the multivariable model shown in Table 2 . The second outcome is type of biopsy ("Type of biopsy determined") and corresponds to the multivariable model shown in Table 3 in which patients are nested within their diagnosing surgeon (the surgeon who saw the patient before biopsy). The third outcome is number of breast cancer surgeries ("More cancer surgery performed?") and corresponds to the multivariable model in Table 4 , in which patients are nested within their treating surgeon (the surgeon who performed the actual breast-conservingmapped. A multilevel, intercept-only model of patients nested within HRR evaluated the proportion of variation in needle biopsy receipt attributable to the HRR level.
For the outcome timing of surgeon consultation, logistic regression identified significant patient and structural factors, with goodness of fit evaluated using the Hosmer-Lemeshow test. For the outcome use of needle biopsy among patients with surgeon consultation before biopsy, data structure was hierarchical with patients nested within diagnosing surgeons. We thus applied a multilevel, random intercept, logistic regression model. [19] [20] [21] [22] [23] [24] [25] A random intercept was included to account for correlated outcomes for patients treated by the same diagnosing surgeon, whereas all predictors were modeled as fixed effects. Using the intercept-only model, the intraclass correlation coefficient was calculated to determine the proportion of total variance attributable to the surgeon level. 19, 26 The ratio of the generalized 2 statistic to its df was evaluated for residual overdispersion. For the outcome of single versus multiple breast cancer surgeries, our data had a hierarchical structure of patients nested within treating surgeons, and thus, a similar multilevel model was used.
For fitting all multivariable models, covariates were included if significant in unadjusted logistic regression at P Ͻ .05. Models were iteratively refined to minimize colinearity, with backward selection to remove covariates without statistically significant effects in the final model. Patients and surgeons with unknown covariate values were excluded. Odds ratios were converted to risk ratios. 27 All analyses were conducted using SAS version 9.3 (SAS Institute, Cary, NC). This study was granted exempt status by The University of Texas MD Anderson Cancer Center Institutional Review Board.
RESULTS
Patient Characteristics and Needle Biopsy Utilization
We identified 89,712 patients, 11,279 diagnosing surgeons, and 12,405 treating surgeons. Median patient age was 74.0 years (interquartile range [IQR], 70 to 79 years), 7.7% of patients (n ϭ 6,937) were nonwhite, 6.1% (n ϭ 5,446) had Medicaid coverage, and 87.3% (n ϭ 77,808) underwent mammography within 60 days before surgeon consultation or needle biopsy (Table 1) . Fifty percent of patients lived within 3.4 miles of a radiologic facility performing needle biopsy, and 90% lived within 18.5 miles of such a facility. Locations of radiologic facilities performing needle biopsy relative to numbers of patients in the cohort at the HRR level are shown in Figure 2A . Table 1 ). Median interval from needle biopsy to BCS was 21 days (IQR, 14 to 29 days), and median interval from BCS to start of radiation was 40 days (IQR, 26 to 62 days).
Geographic Variation in Needle Biopsy Utilization
HRR-level geographic variation was noted in needle biopsy rates, from a low of 24.1% (95% CI, 16.2% to 34.3%; n ϭ 20/83) in Bismarck, ND, to a high of 97.2% (95% CI, 90.3% to 99.2%; n ϭ 69/71) in Lynchburg, VA (Fig 2B) . A map showing HRR-level change in needle biopsy rates over time is available in the Data Supplement. In an intercept-only model of patients nested within HRR, 9.1% of variation in needle biopsy receipt was attributable to the HRR level (P Ͻ .001).
Patient and Structural Predictors of the Timing of Surgeon Consultation Relative to Biopsy
In total, 68.4% of patients (n ϭ 61,312) underwent surgeon consultation before biopsy and 31.6% (n ϭ 28,400) underwent surgeon consultation after biopsy (Fig 1) . Among patients with surgeon consultation before biopsy, 46.3% (n ϭ 28,359) did not undergo needle biopsy, 38.4% (n ϭ 23,528) underwent needle biopsy performed by their surgeon, and 15.4% (n ϭ 9,425) underwent needle biopsy performed by a nonsurgeon (typically a radiologist), for an overall needle biopsy rate of 53.7% (n ϭ 32,953). By definition, all patients with surgeon consultation after biopsy (n ϭ 28,400) underwent needle biopsy. In multivariable analysis (n ϭ 89,712), patient characteristics associated with surgeon consultation before biopsy included older age (70.7% of patients age Ն 80 years underwent prebiopsy surgeon consultation v 67.0% of patients age Ͻ 70 years; relative risk [RR], 1.06; P Ͻ .001), black race (71.1% for blacks v 68.3% for whites; RR, 1.05; P Ͻ .001), Medicaid coverage (73.7% for Medicaid beneficiaries v 68.0% for non-Medicaid beneficiaries; RR, 1.07; P Ͻ .001), comorbid illness (73.6% for comorbidity score Ն 3 v 68.0% for comorbidity score of 0 or 1; RR, 1.07; P Ͻ .001), earlier year of diagnosis (73.9% for diagnosis year 2003 v 61.1% for diagnosis year 2007; RR, 1.14; P Ͻ .001), rural residence (76.9% for rural residence v 66.3% for urban residence; RR, 1.06; P Ͻ .001), longer distance to the nearest radiologic facility performing needle biopsy (74.0% for patients Ͼ 8.1 miles v 67.1% for patients Ͻ 0.7 miles; RR, 1.07; P Ͻ .001), no mammogram in the 60 days before consultation (74.7% for patients without a preconsultation mammogram v 67.4% for patients with a preconsultation mammogram; RR, 1.11; P Ͻ .001), and a visit with a primary care provider (PCP) in the 60 days preceding consultation (69.5% for patients with a PCP visit v 66.2% for patients without a PCP visit; RR, 1.05; P Ͻ .001; Table 2 ).
Patient, Structural, and Surgeon Predictors of Biopsy Type
Among patients with surgeon consultation before biopsy, an intercept-only model (n ϭ 11,279 surgeons and 61,312 patients [68.4% of the overall cohort]) indicated that 28.8% of variation in biopsy type was attributable to the surgeon level (P Ͻ .001). After adding fixed effects, patient and structural factors associated with needle biopsy were similar to those factors associated with prebiopsy surgeon consultation (Table 3) . Surgeon-level factors associated with needle biopsy included lack of board certification (39.2% needle biopsy rate for patients of non-board-certified surgeons v 54.8% for patients of board-certified surgeons; RR, 1.32; P Ͻ .001), training outside the United States (44.1% needle biopsy rate for non-US-trained surgeons v 55.1% for US-trained surgeons; RR, 1.17; P Ͻ .001), earlier decade of medical school graduation (50.9% needle biopsy rate for graduation before 1980 v 64.1% for graduation in the 2000s; RR, 1.49; P Ͻ .001), low case volume (40.3% needle biopsy rate for one to five patients treated in cohort v 64.4% for Ն 20 patients treated in cohort; RR, 1.66; P Ͻ .001), and specialization in general surgery (51.7% needle biopsy rate for general surgeons v 63.4% for surgical oncologists; RR, 1.11; P Ͻ .001).
Association of Needle Biopsy With Number of Breast Cancer Surgeries
Overall, risk of multiple breast cancer surgeries was 33.7% (n ϭ 20,651/61,353) for women who underwent needle biopsy versus 69.6% (n ϭ 19,730/28,359) for women who did not (adjusted RR, 2.08; 95% CI, 2.07 to 2.11; P Ͻ .001). There was only a small difference in risk of multiple breast cancer surgeries based on the type of provider who performed the needle biopsy, with a 32.7% (n ϭ 12,361/37,825) risk of multiple breast cancer surgeries if the needle biopsy was performed by a nonsurgeon compared with a 35.2% (n ϭ 8,290/23,528) risk if the needle biopsy was performed by a surgeon (adjusted RR, 1.03; P ϭ .005; Fig 1, Table 4) . 
DISCUSSION
In this nationally comprehensive study of women undergoing BCS and radiation for incident breast cancer, 68.4% were seen by a surgeon before diagnostic biopsy. Compared with patients with surgeon consultation after biopsy, patients with surgeon consultation before biopsy were more likely to be in their 80s, black, ill, and poor; reside in rural areas; live more than 8.1 miles from a radiologic facility performing needle biopsy; and not undergo mammography before surgeon consultation. In total, only 53.7% of patients with prebiopsy surgeon consultation underwent needle biopsy. The use of needle biopsy was heavily influenced by the patient's surgeon, with patients substantially less likely to undergo needle biopsy if their surgeon was not board certified, not trained in the United States, not a surgical oncologist, not recently trained, or cared for a lower number of patients in the cohort. The importance of the surgeon relative to other factors such as proximity to radiologic facilities is illustrated by the observation that even among patients who lived within just 0.7 miles of a radiologic facility and were seen by a surgeon before biopsy, only 55.2% underwent needle biopsy. Unfortunately, for patients who did not undergo needle biopsy, only 30.4% were able to complete all of their breast surgery in a single procedure, indicating that the majority of such patients underwent one open surgical procedure to diagnose their breast cancer followed by at least one, if not more, additional open surgical procedures to treat it.
Our results are consistent with a recent IOM report entitled, "Variation in Health Care Spending: Target Decision Making, Not Geography," which concluded that significant geographic variation exists in spending and utilization of general medical care and that such variation is largely unexplained. However, variation remains as units of analysis become progressively smaller, such that even within practices and across individual physicians meaningful variation exists. 6 The findings of our study support and strengthen the argument of this IOM report, principally that the proportion of variance in needle biopsy use explained by the treating physician, 28.8%, is substantially greater than the proportion of variance explained by geographic region, 9.1%. Accordingly, our findings support the conclusion of this IOM report, which states that interventions to improve quality and value of care must be focused primarily on influencing provider behavior rather than modifying reimbursement globally in certain highcost or low-value geographic regions.
Our results also identify multiple avenues whereby use of needle biopsy may be increased. Primarily, patients and PCPs should be empowered to partner directly with diagnostic radiologists to evaluate abnormal mammograms or clinical breast findings and to proceed to needle biopsy where appropriate. In addition, efforts to increase access to skilled radiologic facilities may also be beneficial, because patients residing more than 8.1 miles from a radiologic facility were more likely to undergo surgeon consultation before biopsy and less likely to undergo needle biopsy.
Our findings also indicate that surgeons often perform needle biopsy as an alternative to radiologic needle biopsy. Although encouraging surgeons to perform diagnostic biopsy may further increase use of needle biopsy to diagnose breast cancer, particularly in rural areas with suboptimal access to radiologists, prior literature indicates that needle biopsy performed by inexperienced physicians is frequently misleading and even harmful, with up to 25% of cancers missed by untrained physicians, 28 thus underscoring the need for adequate access and appropriate referral to skilled radiologic facilities.
Needle biopsy has been accepted as a diagnostic strategy to evaluate abnormal breast findings since the 1990s.
11 Consensus statements published in 2001, 10 2005, 15 and 2009 9 concluded that needle biopsy should be preferred over excisional biopsy and suggested that physician benchmarks for compliance with needle biopsy should exceed 90%. Needle biopsy achieves diagnostic accuracy similar to open surgical biopsy, but with a lower risk of postprocedure complications. 29 Furthermore, charges for needle biopsy are approximately 50% less than charges for open surgical biopsy; thus, increasing use of needle biopsy could reap substantial cost savings. 30 Needle biopsy also enhances accuracy of lymph node staging, with a false-negative sentinel lymph node rate of 15.3% in women diagnosed with excisional biopsy compared with 8.1% in women diagnosed with needle biopsy. 31 Needle biopsy also serves to establish extent of disease preoperatively and can thus guide surgical decision making regarding whether to perform BCS or mastectomy. A final advantage of needle biopsy is that it provides a woman with information about her diagnosis before initiating surgical therapy and thus empowers her to be more involved in important decisions regarding neoadjuvant therapy, breast conservation versus mastectomy, radiation therapy, and breast reconstruction.
A growing literature has evaluated compliance with needle biopsy in the initial diagnosis of breast cancer. In the 1990s, only 24% of patients with breast cancer underwent needle biopsy. 32 In the 2000s, a population-based study from Florida concluded that 70% of breast biopsies were needle biopsies. 30 A study from the National Cancer Database concluded that use of needle biopsy increased to 87% by 2008. 33 This study was limited, however, in that the definition of needle biopsy included open incisional biopsy, which could have resulted in inaccurately high needle biopsy rates. Furthermore, the National Cancer Database likely overestimates compliance with needle biopsy in the general population, because it includes only institutions participating in the American College of Surgeons Commission on Cancer program.
Results of this study are most applicable to older women with fee-for-service Medicare and may not readily extend to other patients and settings. To select a defined population with incident breast cancer for whom needle biopsy is indicated, we limited our cohort to women treated with BCS and radiation. It is possible that needle biopsy rates may vary in other patient groups with and without breast cancer. Furthermore, some patients in this cohort likely did not undergo needle biopsy as a result of legitimate reasons such as anxiety, transportation difficulties, lack of an imaging correlate for a palpable breast abnormality, or technical contraindications to biopsy, although all of these issues are relatively rare. Finally, although it is likely that needle biopsy rates have continued to increase since 2007, needle biopsy was considered the preferred standard of care during the entirety of our Abbreviations: BCS, breast-conserving surgery; DO, doctor of osteopathy; MD, doctor of medicine; NS, not significant; RR, relative risk.
‫ء‬
Statistical significance evaluated at the P ϭ .05 level in both unadjusted and adjusted analyses. A RR Ͼ 1 indicates that the factor was associated with a lower likelihood of needle biopsy. In this model, 298 surgeons and 1,294 patients were excluded because of unknown covariates. The ratio of the generalized 2 statistic to its df was 0.85, indicating no residual overdispersion in the model. †Surgeon case volume was defined for each surgeon as the number of patients in the cohort who underwent BCS performed by that surgeon during the time interval of the study. study interval, and thus our findings regarding the importance of timing of surgeon consultation relative to biopsy and the relevance of surgeon factors to use of needle biopsy are expected to remain relevant to contemporary practice. It should also be recognized that, to be consistent with the National Quality Forum-endorsed quality measure and prior literature, this study included both fine-needle aspiration and core biopsy in the definition of needle biopsy.
12,13 However, large-bore core needle biopsy is generally the preferred biopsy technique and carries the lowest false-negative rate.
34,35
Needle biopsy continues to be omitted in many patients for whom it is the preferred diagnostic approach, particularly those already known to be vulnerable to disparities in breast cancer care. This gap in quality doubles the likelihood of multiple breast cancer surgeries and has other harmful effects such as increased cost and decreased accuracy of sentinel lymph node biopsy. Surgeon-level interventions are needed to improve use of needle biopsy and, accordingly, quality of care. Abbreviations: BCS, breast-conserving surgery; DO, doctor of osteopathy; MD, doctor of medicine; NS, not significant; RR, relative risk.
AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS
‫ء‬
Statistical significance evaluated at the P ϭ .05 level in both unadjusted and adjusted analyses. A RR Ͼ 1 indicates that the factor was associated with a higher likelihood of multiple (two or more) breast cancer surgeries on separate dates before starting adjuvant radiation therapy. In this model, 392 surgeons and 1,440 patients were excluded as a result of unknown covariates. The ratio of the generalized 2 statistic to its df was 0.91. †Surgeon case volume was defined for each surgeon as the number of patients in the cohort who underwent BCS performed by that surgeon during the time interval of the study.
‡Medical specialty was determined using the coded provider specialty in both the Carrier file and the American Medical Association Physician Masterfile, with either source considered sufficient to document a specialty of surgical oncology. 
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